Who Exports Efavirenz from India — 101 Suppliers Behind a $60.2M Market
India's efavirenz export market is supplied by 101 active exporters who collectively shipped $60.2M across 1,084 shipments. MACLEODS PHARMACEUTICALS LTD leads with a 38.1% market share, followed by MYLAN LABORATORIES LIMITED and CIPLA LIMITED. The top 5 suppliers together control 90.9% of total export value, reflecting a concentrated market structure.
Top Efavirenz Exporters from India — Ranked by Export Value
MACLEODS PHARMACEUTICALS LTD is the leading efavirenz exporter from India, holding a 38.1% share of the $60.2M market across 1,084 shipments from 101 exporters. The top 5 suppliers — MACLEODS PHARMACEUTICALS LTD, MYLAN LABORATORIES LIMITED, CIPLA LIMITED, MACLEODS PHARMACEUTICALS LIMITED, HETERO LABS LIMITED — collectively control 90.9% of total export value, indicating a highly concentrated market. Individual shares are: MACLEODS PHARMACEUTICALS LTD (38.1%), MYLAN LABORATORIES LIMITED (33.4%), CIPLA LIMITED (11.7%), MACLEODS PHARMACEUTICALS LIMITED (4.3%), HETERO LABS LIMITED (3.3%).
Top Efavirenz Exporters from India
Ranked by export value · 101 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MACLEODS PHARMACEUTICALS LTD ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $22.9M | 33 | 38.1% |
| 2 | MYLAN LABORATORIES LIMITED ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $20.1M | 40 | 33.4% |
| 3 | CIPLA LIMITED EFAVIR 600 MG TABLETS [PAC SIZE:1X30X14680 PAC=440400 NOS]EFAVIR 600 MG TABLETS [PAC SIZE:1X30X14608 PAC=438240 NOS]EFAVIR 600 MG TABLETS [PAC SIZE:1X30X14346 PAC=430380 NOS] | $7.0M | 12 | 11.7% |
| 4 | MACLEODS PHARMACEUTICALS LIMITED ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $2.6M | 12 | 4.3% |
| 5 | HETERO LABS LIMITED EFAVIR 600 MG TABLETS [PAC SIZE:1X30X14680 PAC=440400 NOS]EFAVIR 600 MG TABLETS [PAC SIZE:1X30X14608 PAC=438240 NOS]EFAVIR 600 MG TABLETS [PAC SIZE:1X30X14346 PAC=430380 NOS] | $2.0M | 19 | 3.3% |
| 6 | MICRO LABS LIMITED EFAVIRENZ 400MG/LAMIVUDINE 300MG/TENOFOVEFAVIRENZ 400MG /LAMIVUDINE 300MG/TENOFOVIRADAY TAB. (EFAVIRENZ 600 MG+EMTRICIIN | $1.5M | 15 | 2.4% |
| 7 | AUROBINDO PHARMA LTD ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $708.9K | 8 | 1.2% |
| 8 | STRIDES PHARMA SCIENCE LIMITED VIRADAY TAB. (EFAVIRENZ 600 MG+EMTRICIINODITEC TABLETSEFAVIRENZ TABLETS 200 MGTAX INV:706205017/30.11.2023 | $611.0K | 25 | 1.0% |
| 9 | DELTA BIOPHARMA PRIVATE LIMITED VIRADAY TAB. (EFAVIRENZ 600 MG+EMTRICIINODITEC TABLETSEFAVIRENZ TABLETS 200 MGTAX INV:706205017/30.11.2023 | $388.0K | 2 | 0.6% |
| 10 | AUROBINDO PHARMA LIMITED ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $363.3K | 3 | 0.6% |
| 11 | AAGAMA EXPORTS LLP | $285.1K | 1 | 0.5% |
| 12 | SANDOZ PRIVATE LIMITED | $283.0K | 2 | 0.5% |
| 13 | EMCURE PHARMACEUTICALS LIMITED ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $255.1K | 3 | 0.4% |
| 14 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ATROIZA (75827 PACKS X 30S = 22TRIOLAR TABLETS BNO:BEB92310A MD.10/23 ED.09/25 PS: 1X30STRIOLAR TABLETS BNO:BEB92309A MD.09/23 ED.08/25 PS: 1X30S | $253.3K | 7 | 0.4% |
| 15 | ANNORA PHARMA PRIVATE LIMITED EFAVIRENZ TABLETEFAVIRENZ EMTRICITABINE AND TENOFOVIREFAVIRENZ TABLETS 600MG 30'SNOS | $208.6K | 1 | 0.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Efavirenz exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Cipla Limited | Approved | Yes | Yes | Multiple | Cipla is the world's largest manufacturer of antiretroviral drugs. |
| Macleods Pharmaceuticals Ltd | Approved | Yes | Yes | Multiple | Macleods has received multiple ANDA approvals from the US FDA. |
| Micro Labs Limited | Approved | Yes | Yes | Multiple | Micro Labs has received multiple ANDA approvals from the US FDA. |
| Strides Pharma Science Limited | Approved | Yes | Yes | Multiple | Strides has received multiple ANDA approvals from the US FDA. |
| Aurobindo Pharma Ltd | Approved | Yes | Yes | Multiple | Aurobindo has received multiple ANDA approvals from the US FDA. |
| Hetero Labs Limited | Approved | Yes | Yes | Multiple | Hetero has received multiple ANDA approvals from the US FDA. |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | Multiple | Sun Pharma has received multiple ANDA approvals from the US FDA. |
| Emcure Pharmaceuticals Limited | Approved | Yes | Yes | Multiple | Emcure has received multiple ANDA approvals from the US FDA. |
| Annora Pharma Private Limited | Approved | Yes | Yes | Multiple | Annora has received multiple ANDA approvals from the US FDA. |
TransData Nexus reviewed the regulatory standing of 9 leading Efavirenz exporters from India. 9 hold US FDA facility approvals, 9 maintain WHO-GMP certification, and 9 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Efavirenz sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Pharma City of India," is a central hub for pharmaceutical research, manufacturing, and exports. The city contributes nearly 40% of the country's bulk drug production and hosts over 2,000 pharmaceutical companies. This concentration of expertise and infrastructure positions Hyderabad as a pivotal player in the production of active pharmaceutical ingredients (APIs) like Efavirenz.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations. Gujarat leads India with a 33% share in drug manufacturing and a 28% share in drug exports. The region is home to major companies such as Alembic Pharmaceuticals, which specializes in formulations for therapeutic areas including cardiology and infectious diseases. This specialization makes the cluster significant in the production of finished dosage forms of Efavirenz.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products. Its proximity to major ports facilitates the efficient export of medications, including Efavirenz, to international markets. The region's well-established logistics and regulatory infrastructure support the seamless movement of pharmaceutical goods, reinforcing India's position as a leading exporter of generic medicines.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives. These incentives have attracted numerous pharmaceutical companies, contributing to the production of various drugs, including antiretrovirals like Efavirenz. The region's growth underscores the impact of policy measures in shaping India's pharmaceutical landscape.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 90.9% of Efavirenz shipments, it's prudent to diversify sourcing to mitigate risks associated with supplier concentration.
- Leverage Regional Specializations: Engage with manufacturers in Hyderabad for API procurement and collaborate with firms in the Ahmedabad-Vadodara cluster for formulations to optimize the supply chain.
- Utilize Export Infrastructure: Capitalize on the Mumbai-Thane-Raigad region's export capabilities to ensure efficient distribution of Efavirenz to international markets.
- Monitor Policy Changes: Stay informed about tax incentives and regulatory developments in regions like Baddi-Nalagarh to identify cost-effective manufacturing opportunities.
By strategically engaging with these pharmaceutical clusters, stakeholders can enhance the efficiency and resilience of the Efavirenz supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Efavirenz exporters from India
Hetero Labs Limited — CDSCO flags Hetero Labs' drug as 'not of standard quality'
The Central Drugs Standard Control Organisation (CDSCO) listed a batch of Hetero Labs' drug as "not of standard quality" in its August report. - IMPACT: Potential scrutiny on Hetero Labs' manufacturing processes may affect Efavirenz export credibility.
Impact: Potential scrutiny on Hetero Labs' manufacturing processes may affect Efavirenz export credibility.
Cipla Limited — Cipla wins bid to supply generic drugs in China
Cipla secured a bid to supply generic medicines, including Dapagliflozin, to Chinese public hospitals under China's volume-based procurement tender. - IMPACT: This expansion into the Chinese market may enhance Cipla's global presence, potentially boosting Efavirenz exports.
Impact: This expansion into the Chinese market may enhance Cipla's global presence, potentially boosting Efavirenz exports.
Hetero Labs Limited — Hetero Labs chosen to supply generic drugs in China
Hetero Labs was selected to supply generic medicines, including Dapagliflozin, to Chinese public hospitals under China's volume-based procurement tender. - IMPACT: This collaboration may strengthen Hetero Labs' international market position, potentially increasing Efavirenz exports.
Impact: This collaboration may strengthen Hetero Labs' international market position, potentially increasing Efavirenz exports.
Common Questions — Efavirenz Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which efavirenz supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MACLEODS PHARMACEUTICALS LTD leads with 121 recorded shipments worth $22.9M. MYLAN LABORATORIES LIMITED (167 shipments) and CIPLA LIMITED (59 shipments) are also established high-volume exporters.
Q How many efavirenz manufacturers are there in India?
India has 101 active efavirenz exporters with a combined export market of $60.2M across 1,084 shipments to 121 countries. The top 5 suppliers hold 90.9% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for efavirenz from India?
Average FOB unit price: $13.14 per unit, ranging from $0.01 to $1567.33. Average shipment value: $55.5K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 101 verified Indian exporters of Efavirenz ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,084 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 121 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,084 Verified Shipments
101 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists